Did they associate your dysplasia with h pylori? I mean did you have it and then killed it with antibiotics? How did it go? I know people who went through a full optimized bismuth quadruple therapy and then tested positive in 6 months, then repeated the therapy and still live with h pylori. Even quadruple therapy does not sometime eradicate it. It’s not 100% guaranteed. It’s only 97-98%. It’s nice to know though that only 1-3% of the infected population develop cancer. Most people do not. And eradication process is too brutal.
1 Like
I was diagnosed with h pylori about 20 years ago. I was treated with two antibiotics at that time and don’t recall which ones. I’ve had stomach issues ever since. In hindsight it was self inflicted since I drank too much alcohol for years. Abstaining from alcohol and salt are two things high on the list for stomach cancer prevention
1 Like
3 Likes
2 Likes
I think at least in part the cause of both is a deterioration in mtDNA
2 Likes
The data from recent the American Society of Clinical Oncology (ASCO) 2026 annual meeting highlights a critical, often underreported shift in oncology: significant survival gains can be achieved through non-pharmacological interventions, dose optimization, and toxicity management, rather than relying solely on high-cost novel therapeutics.
The following structured analysis categorizes these four key findings by cost-efficiency, detailing their clinical outcomes, systemic economic impacts, and the therapeutic trade-offs presented.
4 Key Clinical Takeaways from ASCO 2026
1. Structured Post-Operative Exercise (Colon Cancer)
- Intervention: A structured physical exercise program implemented following primary treatment for colon cancer.
-
Clinical Outcomes:
- 37% reduction in the relative risk of death.
- 8-Year Survival Rate: 90% in the exercise cohort versus 83% in the usual care cohort.
- Economic Impact: Health economists classified the intervention as “dominant.” In health economics, a dominant strategy is one that simultaneously improves clinical outcomes (extends life) while reducing total healthcare system expenditures relative to the comparator.
2. Ultra-Low-Dose Immunotherapy (Head & Neck Cancer)
- Intervention: Administration of 1/10th of the standard dose of an immune checkpoint inhibitor (programmed death receptor-1 [PD-1] or programmed death-ligand 1 [PD-L1] inhibitor), combined with three generic adjuvant medications.
-
Clinical Outcomes:
- Median Overall Survival (mOS): 10.3 months for the low-dose combination versus 6.2 months for standard-of-care chemotherapy.
- Economic Impact: This regimen costs approximately $230 per month, a fraction of the cost associated with standard-dose checkpoint inhibitors, which frequently exceed $10,000 per month. This protocol, developed by researchers in Mumbai, demonstrates a scalable model for low- and middle-income countries (LMICs).
3. Toxicity Mitigation via Next-Generation Anti-Androgens (Prostate Cancer)
- Intervention: Comparative tolerability of the second-generation androgen receptor inhibitors darolutamide versus enzalutamide in advanced prostate cancer.
- Clinical Outcomes: Both agents demonstrate equivalent efficacy regarding objective response rates and progression-free survival. However, darolutamide resulted in a 50% reduction in the incidence of cognitive impairment (brain fog) compared to enzalutamide.
- Economic & Practical Impact: Because both therapies occupy a similar pricing tier, the financial cost remains neutral. The clinical “win” relies entirely on provider education and patient advocacy to select the agent with the superior central nervous system (CNS) safety profile.
4. High-Cost Targeted Combination Therapy (BRAF-Mutant Colon Cancer)
- Intervention: A combination regimen targeting the BRAF V600E mutation in metastatic colorectal cancer.
-
Clinical Outcomes:
- Median Overall Survival (mOS): Doubled to 30 months compared to 15 months with standard chemotherapy controls.
- Economic & Practical Impact: This represents a high-cost specialty therapeutic intervention. Unlike many marginal oncology approvals, the substantial magnitude of the survival benefit (1:2 survival ratio) provides a clear clinical justification for the financial expenditure.
Clinical Implications & Paradigm Shift
The 2026 data challenges the prevailing assumption that advancing oncology care inherently requires exponential financial investment. The findings establish three distinct pathways for improving patient outcomes:
| Pathway | Mechanism | Primary Barrier |
|---|---|---|
| Behavioral Oncology | Epigenetic and metabolic modulation via structured exercise. | Care coordination and patient adherence tracking. |
| Pharmacokinetic De-escalation | Low-dose checkpoint inhibition maintaining therapeutic efficacy. | Regulatory frameworks and pharmaceutical margin misalignments. |
| Selective Prescribing | Prioritizing agents with lower blood-brain barrier penetration (darolutamide). | Physician awareness and default prescribing habits. |
Scholarly Note & Knowledge Gaps: While the Mumbai low-dose immunotherapy trial offers a compelling model for global health equity, further multi-center genomic and pharmacokinetic validating data are required to confirm if these results can be generalized across diverse patient populations with different mutational burdens. Additionally, the exact molecular pathways by which exercise mitigates colon cancer recurrence (e.g., insulin-like growth factor [IGF] signaling pathways, systemic inflammation reduction) remain an active area of biomarker exploration.
Source: https://x.com/agingroy/status/2061470328061059454?s=20